Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05922657 · ClinicalTrials.gov registry record

A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device

A clinical trial of Menorrhagia and Heavy Menstrual Bleeding, sponsored by Channel Medsystems.

Recruiting
Registry status
300
Enrollment target
2
Study locations

NCT05922657 is a study of Menorrhagia and Heavy Menstrual Bleeding that is actively recruiting participants, run by Channel Medsystems. The registered enrollment target is 300 participants, above the 199-participant average among 10 other Menorrhagia trials with a reported enrollment target (51% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05922657, a study of Menorrhagia and Heavy Menstrual Bleeding, is actively recruiting participants, sponsored by Channel Medsystems.

RECRUITING
Registry status
300 participants
Enrollment target
2
Study locations

Study Summary

Channel Medsystems, Inc., the manufacturer of the Cerene® Cryotherapy Device (Cerene), is initiating a prospective, observational registry, the Progress registry, to gather data during real world utilization of the Cerene® Cryotherapy Device (Cerene). The primary objective of this registry is to bridge the gap between clinical results and outcomes achieved and reported during the pivotal study of Cerene and those obtained during its real-world use.

Interventions

  • DEVICE Cerene

Study Locations (2)

New Jersey

  • Axia Women's Health / Rubino OB/GYN Group - West Orange

Ohio

  • Seven Hills Women's Health Centers - Cincinnati

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2023-06-09
Est. Completion 2027-12-31

Sponsor

Channel Medsystems

2 total trials

What the Registry Record Tells You About NCT05922657

The ClinicalTrials.gov registry entry for NCT05922657 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 199-participant average among 10 other Menorrhagia trials with a reported enrollment target (51% higher). The listed sponsor is Channel Medsystems, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Menorrhagia appearing as the primary indexed condition, and to 1 intervention - of which Cerene is the first listed.

NCT05922657 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Ohio.

Frequently Asked Questions

What is clinical trial NCT05922657 about?

NCT05922657 is a clinical study titled "A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device". Channel Medsystems, Inc., the manufacturer of the Cerene® Cryotherapy Device (Cerene), is initiating a prospective, observational registry, the Progress registry, to gather data during real world utilization of the Cerene® Cryotherapy Device (Cerene). The primary objective of this registry is to bri...

What is the current status of trial NCT05922657?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2023-06-09. Estimated completion is 2027-12-31.

What conditions does trial NCT05922657 study?

This clinical trial studies the following conditions: Menorrhagia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding.

What interventions are being tested in trial NCT05922657?

The interventions under investigation include: Cerene (DEVICE).

Who is sponsoring clinical trial NCT05922657?

This trial is sponsored by Channel Medsystems, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05922657 being conducted?

This trial has 2 study locations across New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Menorrhagia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.